# EDGAR Filing Document

**Accession Number:** 0001941029
**File Stem:** 0001213900-26-073735
**Filing Date:** 2026-6
**Character Count:** 24303
**Document Hash:** 70e0d0336c9d01c7792e23c7aa0539ac
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-073735.hdr.sgml**: 20260630

**ACCESSION NUMBER**: 0001213900-26-073735

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260630

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260630

**DATE AS OF CHANGE**: 20260630

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Advanced Biomed Inc.
- **CENTRAL INDEX KEY:** 0001941029
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42548
- **FILM NUMBER:** 261140987

**BUSINESS ADDRESS:**
- **STREET 1:** 401 RYLAND ST
- **STREET 2:** STE 200-A
- **CITY:** RENO
- **STATE:** NV
- **ZIP:** 89502
- **BUSINESS PHONE:** 86-21-20510823

**MAIL ADDRESS:**
- **STREET 1:** 401 RYLAND ST
- **STREET 2:** STE 200-A
- **CITY:** RENO
- **STATE:** NV
- **ZIP:** 89502

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**June 30, 2026**

Date of Report (Date of earliest event reported)

**Advanced Biomed Inc.**

(Exact name of Company as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-42548** | **87-2177170** |
| (State or other jurisdiction<br> of Incorporation) | (Commission File Number) | (IRS Employer<br> Identification Number) |

---

**No. 689-85 Xiaodong Road, Yongkang District**

**Tainan City, Taiwan** 

(Address of principal executive offices)

**886-6-3121716**

(Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| <br> **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock | ADVB | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01 Entry into a Material Definitive Agreement.**

On June 30, 2026, Advanced Biomed Inc. (the "Company") entered into a Share Purchase Agreement (the "Agreement") with an unrelated third party, pursuant to which the Company agreed to sell 100% of the issued and outstanding shares of Advanced Biomed Inc. (Taiwan), a company organized under the laws of Taiwan (the Republic of China) and a wholly-owned subsidiary of the Company (the "Taiwan Subsidiary"), for an aggregate purchase price of US$490,000, subject to the terms and conditions set forth in the Agreement. The transaction is expected to close within three (3) months from the date of the Agreement.

The Taiwan Subsidiary conducts the Company's biomedical research and development operations, including the A+PerfusC integrated perfusion 3D cell culture platform. Following completion of the transaction, the Company will continue to operate its remaining businesses, including the AI-focused operations conducted through Acellent Technologies (Hong Kong) Co. Limited.

The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Forward-Looking Statements.**

This Current Report on Form 8-K contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Factors that could cause actual results to differ include, among others, the satisfaction of closing conditions, the Company's strategic direction and operations following the Disposition, and the other factors discussed in the Company's filings with the SEC. The Company undertakes no obligation to publicly update any forward-looking statement except as required by law.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1 | [Share Purchase Agreement, dated as of June 30, 2026](ea029652901ex10-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Advanced Biomed Inc.** | **Advanced Biomed Inc.** |
| Date: June 30, 2026 | By: | */s/ Xiaomin Chen* |
|  |  | Xiaomin Chen |
|  |  | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**SHARE PURCHASE AGREEMENT**

This Share Purchase Agreement (this "**Agreement**"), dated as of June 30, 2026, is entered into by and among Advanced Biomed Inc., a Nevada corporation ("**Seller**"), Miaozhu Zhao (the "**Buyer**") and Advanced Biomed Inc. (Taiwan), a company organized under the laws of Taiwan (the Republic of China) and a wholly-owned subsidiary of the Seller (the "**Target**"). Capitalized terms used in this Agreement have the meanings given to such terms herein.

**RECITALS**

**WHEREAS**, Seller owns all of the issued and outstanding equity interest of the Target;

**WHEREAS**, Seller wishes to sell to Buyer, and Buyer wishes to purchase from Seller, all of the issued and outstanding equity interest of the Target (the "**Target Equity Interest**"), subject to the terms and conditions set forth herein; and

**NOW, THEREFORE**, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

**ARTICLE I<br> Purchase and sale**

**Section 1.01 Purchase and Sale.** Subject to the terms and conditions set forth herein, at the Closing (as defined in Section 2.01), Seller shall sell to Buyer, and Buyer shall purchase from Seller, the Target Equity Interest, free and clear of any mortgage, pledge, lien, charge, security interest, claim, community property interest, option, equitable interest, restriction of any kind (including any restriction on use, voting, transfer, receipt of income, or exercise of any other ownership attribute), or other encumbrance (each, an "**Encumbrance**").

**Section 1.02 Purchase Price.** The aggregate purchase price for the Target Equity Interest shall be $490,000 (the "**Purchase Price**"), payable in cash by wire transfer of immediately available funds at Closing (as defined in Section 2.01).

**ARTICLE II<br> CLOSING**

**Section 2.01 Closing.** The closing of the transactions contemplated by this Agreement (the "**Closing**") shall take place on a date mutually agreed by the parties within three (3) months from the date hereof (the "**Closing Date**").

**Section 2.02 Seller Closing Deliverables.** At the Closing, Seller shall deliver the Target Equity Interest to Buyer.

**Section 2.03 Buyer Closing Deliverables.** At the Closing, Buyer shall deliver the Purchase Price to Seller.

**ARTICLE III<br> Representations and warranties of seller**

Seller represents and warrants to Buyer that the statements contained in this Article III are true and correct as of the date hereof.

**Section 3.01 Organization and Authority of Seller.** Seller is a company duly organized, validly existing, and in good standing under the Laws (as defined in Section 3.02) of the State of Nevada. Seller has full corporate power and authority to enter into this Agreement, to carry out its obligations hereunder, and to consummate the transactions contemplated hereby. The execution and delivery by Seller of this Agreement, the performance by Seller of its obligations hereunder, and the consummation by Seller of the transactions contemplated hereby have been duly authorized by all requisite corporate action on the part of Seller. This Agreement constitutes a legal, valid and binding obligation of Seller enforceable against Seller in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors' rights generally and by general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity).

**Section 3.02 No Conflicts or Consents.** The execution, delivery, and performance by Seller of this Agreement, and the consummation of the transactions contemplated hereby, do not and will not: (a) violate or conflict with any provision of the memorandum and articles of associations, as amended, of the Seller; (b) violate or conflict with any provision of any Law or Governmental Order applicable to Seller ; (c) require the consent, notice or other action by any Person under, violate or conflict with, or result in the acceleration of any agreement to which Seller is a party; (d) require any consent, permit, Governmental Order, filing or notice from, with or to any Governmental Authority; except, in the cases of clauses (b) and (c), where the violation, conflict, acceleration or failure to obtain consent or give notice would not have a Material Adverse Effect and, in the case of clause (d), where such consent, permit, Governmental Order, filing or notice which, in the aggregate, would not have a Material Adverse Effect. For purposes of this Agreement: (i) "**Law**" means any statute, law, ordinance, regulation, rule, code, order, constitution, treaty, common law or other requirement or rule of law of any Governmental Authority; (ii) "**Governmental Order**" means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any Governmental Authority; (iii) "**Governmental Authority**" means any federal, state, local or foreign government or political subdivision thereof, or any agency or instrumentality of such government or political subdivision, or any arbitrator, court or tribunal of competent jurisdiction; (iv) "**Person**" means an individual, corporation, partnership, joint venture, limited liability company, Governmental Authority, unincorporated organization, trust, association or other entity; and (v) "**Material Adverse Effect**" means any event, occurrence, fact, condition or change that is materially adverse to the business, results of operations, financial condition or assets of the Company, taken as a whole.

**Section 3.03 Title of Target Equity Interest**. Seller has good and valid title to all the Target Equity Interest, free and clear of any Encumbrance.

**Section 3.04 Legal Proceedings; Governmental Orders**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) There are no claims, actions, causes of action, demands, lawsuits, arbitrations, inquiries, audits, notices of violation, proceedings, litigation, citations, summons, subpoenas, or investigations of any nature, whether at law or in equity (collectively, "**Actions**") pending or threatened against or by Seller: (i) relating to or affecting the Target Equity Interest; or (ii) that challenge or seek to prevent, enjoin, or otherwise delay the transactions contemplated by this Agreement. No event has occurred or circumstances exist that may give rise to, or serve as a basis for, any such Action.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) There are no outstanding Governmental Orders against, relating to, or affecting the Target Equity Interest.

**ARTICLE IV<br> Representations and warranties of THE TARGET**

The Target represents and warrants to Buyer that the statements contained in this Article V are true and correct as of the date hereof.

**Section 4.01 Organizations, Authority, and Qualification of the Target**. The Target is a company duly organized, validly existing, and in good standing under the Laws of Taiwan (the Republic of China) and has full corporate power and authority to own, operate, or lease the properties and assets now owned, operated, or leased by it and to carry on its business as it is currently conducted. The Target is duly licensed or qualified to do business and is in good standing in each jurisdiction in which the properties owned or leased by it or the operation of its business as currently conducted makes such licensing or qualification necessary, except where the failure to be so licensed, qualified or in good standing would not have a Material Adverse Effect. All corporate actions taken by the Target in connection with this Agreement have been duly authorized.

**Section 4.02 No Conflicts or Consents.** The execution, delivery, and performance by the Target of this Agreement, and the consummation of the transactions contemplated hereby, do not and will not: (a) violate or conflict with any provision of the memorandum and articles of associations, as amended, of the Target; (b) violate or conflict with any provision of any Law or Governmental Order applicable to the Target; (c) require the consent, notice or other action by any Person under, violate or conflict with, or result in the acceleration of any agreement to which the Target is a party; (d) require any consent, permit, Governmental Order, filing or notice from, with or to any Governmental Authority; except, in the cases of clauses (b) and (c), where the violation, conflict, acceleration or failure to obtain consent or give notice would not have a Material Adverse Effect and, in the case of clause (d), where such consent, permit, Governmental Order, filing or notice which, in the aggregate, would not have a Material Adverse Effect.

**Section 4.03 Due Issuance of the Target Equity Interest**. The Target Equity Interest were duly authorized, fully paid, non-assessable, validly issued and free of any Encumbrance.

**Section 4.04 Title to Assets**. Target has good and valid title to all its assets, free and clear of any Encumbrance.

**Section 4.05 Legal Proceedings; Governmental Orders**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) There are no Actions pending or threatened against or by the Target: (i) relating to or affecting the business of the Target or the Target Equity Interest; or (ii) that challenge or seek to prevent, enjoin, or otherwise delay the transactions contemplated by this Agreement. No event has occurred or circumstances exist that may give rise to, or serve as a basis for, any such Action.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) There are no outstanding Governmental Orders against, relating to, or affecting the business of the Target or the Target Equity Interest.

**Section 4.06 Compliance with Laws of the Target**. The Target is in compliance with all Laws applicable to the conduct of the Business.

**ARTICLE V<br> Representations and warranties of Buyer**

Buyer represents and warrants to Seller and the Target that the statements contained in this Article V are true and correct as of the date hereof.

**Section 5.01 Binding Agreement**. This Agreement constitutes a legal, valid and binding obligation of Buyer enforceable against Buyer in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors' rights generally and by general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity).

**Section 5.02 No Conflicts; Consents.** The execution, delivery and performance by Buyer of this Agreement, and the consummation of the transactions contemplated hereby, do not and will not: (a) violate or conflict with any provision of any Law or Governmental Order applicable to Buyer; (c) require the consent, notice or other action by any Person under, violate or conflict with, or result in the acceleration of any agreement to which Buyer is a party; or (d) require any consent, permit, Governmental Order, filing or notice from, with or to any Governmental Authority; except, in the cases of clauses (b) and (c), where the violation, conflict, acceleration or failure to obtain consent or give notice would not have a material adverse effect on the buyer's ability to consummate the transactions contemplated hereby and, in the case of clause (d), where such consent, permit, Governmental Order, filing or notice which, in the aggregate, would not have a material adverse effect on the buyer's ability to consummate the transactions contemplated hereby.

**Section 5.03 Investment Purpose.** Buyer is acquiring the Target Equity Interest solely for its own account for investment purposes and not with a view to, or for offer or sale in connection with, any distribution thereof or any other security related thereto within the meaning of the Securities Act of 1933, as amended (the "**Securities Act**"). Buyer acknowledges that Seller has not registered the offer and sale of the Target Equity Interest under the Securities Act or any state securities laws, and that the Target Equity Interest may not be pledged, transferred, sold, offered for sale, hypothecated or otherwise disposed of except pursuant to the registration provisions of the Securities Act or pursuant to an applicable exemption therefrom and subject to state securities laws and regulations, as applicable. Buyer is able to bear the economic risk of holding the Target Equity Interest for an indefinite period (including total loss of its investment), and has sufficient knowledge and experience in financial and business matters so as to be capable of evaluating the merits and risk of its investment.

**Section 5.04 Brokers.** No broker, finder, or investment banker is entitled to any brokerage, finder's or other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Buyer.

**Section 5.05 Independent Investigation.** Buyer has conducted its own independent investigation, review and analysis of the Target, and acknowledges that it has been provided adequate access to the personnel, properties, assets, premises, books and records and other documents and data of Seller and the Target for such purpose. Buyer acknowledges and agrees that: (a) in making its decision to enter into this Agreement and to consummate the transactions contemplated hereby, Buyer has relied solely upon its own investigation and the express representations and warranties of Seller set forth in Article III of this Agreement and the express representations and warranties of Target set forth in Article IV of this Agreement; and (b) none of Seller, the Target or any other Person has made any representation or warranty as to Seller, the Target or this Agreement, except as expressly set forth in Article III and Article IV of this Agreement.

**ARTICLE VI<br> Miscellaneous**

**Section 6.01 Interpretation; Headings.** This Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any instrument to be drafted. The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.

**Section 6.02 Severability.** If any term or provision of this Agreement is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality, or unenforceability shall not affect any other term or provision of this Agreement.

**Section 6.03 Entire Agreement.** This Agreement constitutes the sole and entire agreement of the parties to this Agreement with respect to the subject matter contained herein, and supersede all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter. In the event of any inconsistency between the statements in the body of this Agreement, and any exhibits, the statements in the body of this Agreement will control.

**Section 6.04 Successors and Assigns.** This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns. Neither party may assign its rights or obligations hereunder without the prior written consent of the other parties, which consent shall not be unreasonably withheld or delayed. No assignment shall relieve the assigning party of any of its obligations hereunder.

**Section 6.05 Amendment and Modification; Waiver.** This Agreement may only be amended**,** modified, or supplemented by an agreement in writing signed by each party hereto. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving. No failure to exercise, or delay in exercising, any right or remedy arising from this Agreement shall operate or be construed as a waiver thereof. No single or partial exercise of any right or remedy hereunder shall preclude any other or further exercise thereof or the exercise of any other right or remedy.

**Section 6.06 Governing Law; Submission to Jurisdiction.** This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York, without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction). Any legal suit, action, proceeding, or dispute arising out of or related to this Agreement or the transactions contemplated hereby may be instituted in the federal courts of the United States of America or the courts of the State of New York in each case located in the city of New York and county of New York, and each party irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action, proceeding, or dispute.

**Section 6.07 Counterparts.** This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by email or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

[signature page follows]

**IN WITNESS WHEREOF**, the parties hereto have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.

---

| | |
|:---|:---|
| **Seller** | **Seller** |
| **Advanced Biomed Inc.** | **Advanced Biomed Inc.** |
| By | */s/ Xiaomin Chen* |
| Name: | Xiaomin Chen |
| Title: | Chief Executive Officer |
| **Buyer** | **Buyer** |
| **Miaozhu Zhao** | **Miaozhu Zhao** |
| By | /s/ Miaozhu Zhao |
| Name: | Miaozhu Zhao |
| **Target** | **Target** |
| **Advanced Biomed Inc. (Taiwan)** | **Advanced Biomed Inc. (Taiwan)** |
| By | /s/ Hao Min Cheng |
| Name: | Hao Min Cheng |
| Title: | Director |

---